DaunorubicinThird Party Manufacturing in India

Daunorubicin works by intercalating between DNA base pairs and inhibiting topoisomerase II, which prevents the re-ligation of DNA strands and induces double-strand breaks. It also undergoes intracellular reduction to form highly reactive free radicals that damage cell membrane lipids and vital cellular proteins. Unlike standard alkylators, its multi-faceted anthracycline structure blocks both replication enzymes and structural stability simultaneously. It is highly effective and well-tolerated when monitored for cumulative cardiac exposure.

Therapeutic Uses

• Acute Lymphocytic Leukemia: Integrated into primary remissions induction protocols for both children and adults.
• Acute Myelogenous Leukemia: Utilized as a primary anthracycline option in the classic '7+3' treatment regimen.

Why Manufacturers Choose Daunorubicin

Daunorubicin third party manufacturing in India fulfills a steady demand driven by universal protocol mandates for managing acute leukemia forms. Formulation buyers seek reliable outsourcing networks to avoid the steep capital requirements of building isolated anthracycline handling suites. Our partner facilities offer fully segregated high-containment zones operated under WHO-GMP compliance, ensuring the safe processing of CAS 20830-81-3 into stable lyophilized injection forms.